| NET LOSS PER SHARE |
NET LOSS PER SHARE The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30 (in thousands, except for per share amounts):
| | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
September 30, | | Nine Months Ended
September 30, | | 2024 | | 2023 | | 2024 | | 2023 | | Loss from continuing operations, net noncontrolling interests and accrued preferred stock dividends | $ | (56,117) | | | $ | (578,514) | | | $ | (127,721) | | | $ | (717,946) | | | Loss from discontinued operations | (14,358) | | | (67,843) | | | (42,662) | | | (240,321) | | Net loss attributable to NeueHealth, Inc. common shareholders | $ | (70,475) | | | $ | (646,357) | | | $ | (170,383) | | | $ | (958,267) | | Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted | 8,282 | | | 7,977 | | | 8,205 | | | 7,945 | | | Basic and diluted loss per share attributable to NeueHealth, Inc. common shareholders | | Continuing operations | $ | (6.78) | | | $ | (72.52) | | | $ | (15.57) | | | $ | (90.36) | | | Discontinued operations | $ | (1.73) | | | $ | (8.51) | | | $ | (5.20) | | | $ | (30.25) | | Net loss per share attributable to common stockholders, basic and diluted | $ | (8.51) | | | $ | (81.03) | | | $ | (20.77) | | | $ | (120.61) | |
The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive effect for the nine months ended September 30 (in thousands):
| | | | | | | | | | | | | Nine Months Ended
September 30, | | 2024 | | 2023 | | Redeemable convertible preferred stock (as converted to common stock) | 5,307 | | | 4,599 | | | Issued and outstanding common stock warrants | 2,842 | | | 1,381 | | | Stock options to purchase common stock | 494 | | | 673 | | | Restricted stock units | 3,028 | | | 1,056 | | | Total | 11,671 | | | 7,709 | |
If the liability classified share-based award, as described in Note 6. Share-Based Compensation, is settled in shares in lieu of a cash settlement additional, potentially dilutive securities, will be issued. Until the determination is made, the number of outstanding potentially dilutive securities is not determinable or estimable.
|